ArticleDrug delivery2022
A novel saponin liposomes based on the couplet medicines of
Article in Drug delivery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Efficacy and potential pharmacological mechanism ofRenal failure · 2025Pooled it
- Nanoparticle Engineering in Modern Vaccinology: From Delivery Platforms to Immune-Programming Architectures.Molecules (Basel, Switzerland) · 2026Review
- Dual-targeted liposomes delivering ginsenoside CK attenuate cerebral ischemia-reperfusion injury by suppressing PANoptosis via O-GlcNAcylation of RIPK1/RIPK3.Journal of ginseng research · 2026Article
- Advances in Drug Delivery Systems Utilizing Glycyrrhizic Acid and Its Aglycone Glycyrrhetinic Acid in Cancer Therapy.International journal of nanomedicine · 2026Review
- Developments and Assessments of Crude Tea Saponin-Incorporated Silica Nanoparticles for Their Bioactivity Improvement.Journal of functional biomaterials · 2025Article
- Effect of Jiegeng () on Jingjie () "" into the lungs based on pharmacokinetics.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Exploration of the optimal concentration of quercetin liposome nanoparticles for the treatment of liver damage.BMC pharmacology & toxicology · 2025Article
- Traditional Chinese medicine in lung cancer treatment.Molecular cancer · 2025Review
- Biological insights and therapeutic potential of Glycyrrhiza uralensis and its bioactive compounds: an updated review.Archives of pharmacal research · 2024Review
- Nano-based drug delivery systems for active ingredients from traditional Chinese medicine: Harnessing the power of nanotechnology.Frontiers in pharmacology · 2024Review
- Tumor-targeted liposomes with platycodin D2 promote apoptosis in colorectal cancer.Materials today. Bio · 2023Review
- Potential Targets and Mechanisms of Bitter Almond-Licorice for COVID-19 Treatment Based on Network Pharmacology and Molecular Docking.Current pharmaceutical design · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liposomes have been widely used for targeted drug delivery, but the disadvantages caused by cholesterol limit the application of conventional liposomes in cancer treatment. The compatibility basis of couplet medicines and the compatibility principle of the traditional Chinese medicine principle of 'monarch, minister, assistant and guide' are the important theoretical basis of Chinese medicine in the treatment of tumor and the important method to solve the problem of high toxicity. In this study, the active ingredients of the couplet medicines
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.